Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification

Kentaro Inamura, Kentaro Inamura

Abstract

Lung cancer is the leading cause of cancer-related death worldwide due to late diagnoses and limited treatment interventions. Recently, comprehensive molecular profiles of lung cancer have been identified. These novel characteristics have enhanced the understanding of the molecular pathology of lung cancer. The identification of driver genetic alterations and potential molecular targets has resulted in molecular-targeted therapies for an increasing number of lung cancer patients. Thus, the histopathological classification of lung cancer was modified in accordance with the increased understanding of molecular profiles. This review focuses on recent developments in the molecular profiling of lung cancer and provides perspectives on updated diagnostic concepts in the new 2015 WHO classification. The WHO classification will require additional revisions to allow for reliable, clinically meaningful tumor diagnoses as we gain a better understanding of the molecular characteristics of lung cancer.

Keywords: adenocarcinoma; driver mutation; genetic alteration; histology; lung cancer; molecular pathology.

Figures

Figure 1
Figure 1
Solid adenocarcinoma (A–C) and non-keratinizing squamous cell carcinoma (SqCC) (D–F). Solid adenocarcinoma [(A) HE staining] is immunohistochemically positive for TTF-1 (B) and Napsin A (C). Non-keratinizing SqCC [(D) HE staining] is immunohistochemically positive for p40 (E) and CK5/6 (F).

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin (2015) 65(2):87–108.10.3322/caac.21262
    1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed Lyon: IARC; (2015).
    1. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 511(7511):543–50.10.1038/nature13385
    1. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 489(7417):519–25.10.1038/nature11404
    1. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature (2015) 524(7563):47–53.10.1038/nature14664
    1. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 44(10):1111–6.10.1038/ng.2405
    1. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 44(10):1104–10.10.1038/ng.2396
    1. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 8(8):816–24.10.1038/nm733
    1. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497–500.10.1126/science.1099314
    1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350(21):2129–39.10.1056/NEJMoa040938
    1. Inamura K, Fujiwara T, Hoshida Y, Isagawa T, Jones MH, Virtanen C, et al. Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene (2005) 24(47):7105–13.10.1038/sj.onc.1208858
    1. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 9(3):189–98.10.1016/j.ccr.2006.01.025
    1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448(7153):561–6.10.1038/nature05945
    1. Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Satoh Y, et al. Let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer (2007) 58(3):392–6.10.1016/j.lungcan.2007.07.013
    1. Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent advances in immunotherapy in metastatic NSCLC. Front Oncol (2015) 6:239.10.3389/fonc.2016.00239
    1. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 348(6230):124–8.10.1126/science.aaa1348
    1. Inamura K, Yokouchi Y, Sakakibara R, Kobayashi M, Subat S, Ninomiya H, et al. Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma. Jpn J Clin Oncol (2016) 46(10):935–41.10.1093/jjco/hyw087
    1. Mirzapoiazova T, Mambetsariev N, Lennon FE, Mambetsariev B, Berlind JE, Salgia R, et al. HABP2 is a novel regulator of hyaluronan-mediated human lung cancer progression. Front Oncol (2015) 5:164.10.3389/fonc.2015.00164
    1. Hwang DH, Sholl LM, Rojas-Rudilla V, Hall DL, Shivdasani P, Garcia EP, et al. KRAS and NKX2-1 mutations in invasive mucinous adenocarcinoma of the lung. J Thorac Oncol (2016) 11(4):496–503.10.1016/j.jtho.2016.01.010
    1. Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, et al. Small cell lung cancer screen of oncology drugs, investigational agents, and gene and microRNA expression. J Natl Cancer Inst (2016) 108(10):djw122.10.1093/jnci/djw122
    1. Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent advances in targetable therapeutics in metastatic non-squamous NSCLC. Front Oncol (2016) 6:112.10.3389/fonc.2016.00112
    1. Inamura K, Yokouchi Y, Kobayashi M, Sakakibara R, Ninomiya H, Subat S, et al. Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer (2017) 103:44–51.10.1016/j.lungcan.2016.11.013
    1. Kim H, Yang JM, Jin Y, Jheon S, Kim K, Lee CT, et al. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status. Oncotarget (2017) 8(5):8484–98.10.18632/oncotarget.14298
    1. Saruwatari K, Ikemura S, Sekihara K, Kuwata T, Fujii S, Umemura S, et al. Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations. Lung Cancer (2016) 91:7–14.10.1016/j.lungcan.2015.11.012
    1. Inamura K, Yokouchi Y, Kobayashi M, Ninomiya H, Sakakibara R, Subat S, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget (2017) 8(17):28725–35.10.18632/oncotarget.5647
    1. Zhang Y, Li ZY, Hou XX, Wang X, Luo YH, Ying YP, et al. Clinical significance and effect of AEG-1 on the proliferation, invasion, and migration of NSCLC: a study based on immunohistochemistry, TCGA, bioinformatics, in vitro and in vivo verification. Oncotarget (2017) 8(10):16531–52.10.18632/oncotarget.4972
    1. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 6(2):244–85.10.1097/JTO.0b013e318206a221
    1. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol (2012) 25(3):405–15.10.1038/modpathol.2011.173
    1. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer (1995) 75(12):2844–52.10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>;2-#
    1. Inamura K, Satoh Y, Okumura S, Nakagawa K, Tsuchiya E, Fukayama M, et al. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol (2005) 29(5):660–5.10.1097/01.pas.0000160438.00652.8b
    1. Crabtree JS, Singleton CS, Miele L. Notch signaling in neuroendocrine tumors. Front Oncol (2016) 6:94.10.3389/fonc.2016.00094
    1. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 97(5):339–46.10.1093/jnci/dji055
    1. Ninomiya H, Hiramatsu M, Inamura K, Nomura K, Okui M, Miyoshi T, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type. Lung Cancer (2009) 63(2):235–40.10.1016/j.lungcan.2008.04.017
    1. Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med (2010) 134(1):66–72.10.1043/2008-0586-RAR1.1
    1. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 18(3):378–81.10.1038/nm.2658
    1. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 18(3):375–7.10.1038/nm.2644
    1. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol (2008) 3(1):13–7.10.1097/JTO.0b013e31815e8b60
    1. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 27(26):4247–53.10.1200/JCO.2009.22.6993
    1. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol (2009) 22(4):508–15.10.1038/modpathol.2009.2
    1. Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol (2013) 37(4):554–62.10.1097/PAS.0b013e3182758fe6
    1. Tsuta K, Kohno T, Yoshida A, Shimada Y, Asamura H, Furuta K, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer (2014) 110(6):1571–8.10.1038/bjc.2014.36
    1. Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med (2013) 19(11):1469–72.10.1038/nm.3352
    1. Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Hoang Ho Q, et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J Thorac Oncol (2015) 10(8):1156–62.10.1097/JTO.0000000000000579
    1. Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov (2014) 4(4):415–22.10.1158/-13-0633
    1. Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res (2014) 20(12):3087–93.10.1158/1078-0432.CCR-14-0107
    1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 116(2):281–97.10.1016/S0092-8674(04)00045-5
    1. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature (2005) 435(7043):834–8.10.1038/nature03702
    1. Inamura K, Ishikawa Y. MicroRNA in lung cancer: novel biomarkers and potential tools for treatment. J Clin Med (2016) 5(3):36.10.3390/jcm5030036
    1. Kuninty PR, Schnittert J, Storm G, Prakash J. MicroRNA targeting to modulate tumor microenvironment. Front Oncol (2016) 6:3.10.3389/fonc.2016.00003
    1. Jahagirdar D, Purohit S, Jain A, Sharma NK. Export of microRNAs: a bridge between breast carcinoma and their neighboring cells. Front Oncol (2016) 6:147.10.3389/fonc.2016.00147
    1. Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB, et al. A microRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res (2014) 20(12):3107–17.10.1158/1078-0432.CCR-13-3348
    1. Garajová I, Funel N, Fiorentino M, Agostini V, Ferracin M, Negrini M, et al. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma – a step towards personalized therapy. Clin Epigenetics (2015) 7:129.10.1186/s13148-015-0162-5
    1. Nishikawa E, Osada H, Okazaki Y, Arima C, Tomida S, Tatematsu Y, et al. miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. Cancer Res (2011) 71(19):6165–73.10.1158/0008-5472.CAN-11-1020
    1. Yu Y, Zuo J, Tan Q, Zar Thin K, Li P, Zhu M, et al. Plasma miR-92a-2 as a biomarker for small cell lung cancer. Cancer Biomark (2017) 18(3):319–27.10.3233/CBM-160254
    1. Demes M, Aszyk C, Bartsch H, Schirren J, Fisseler-Eckhoff A. Differential miRNA-expression as an adjunctive diagnostic tool in neuroendocrine tumors of the lung. Cancers (Basel) (2016) 8(4):38.10.3390/cancers8040038

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren